ResMed Inc. (RMD) falls after hours as investors react to a softer fiscal 2027 outlook tied to suspended ventilator sales and higher cost pressure. The company still topped Q4 EPS estimates and posted solid full-year revenue growth, but guidance concerns are driving the selloff.
ResMed Inc. (RMD) fell 12.5% in after-hours trading after investors focused on a softer fiscal 2027 outlook, not on the company’s latest quarter. The pressure stems from suspended ventilator sales after an FDA Class 1 recall and rising component and freight costs, which cloud near-term earnings visibility. For investors, the selloff looks like a guidance reset rather than a breakdown in the core sleep-health franchise.
ResMed Inc. (RMD) falls sharply in after-hours trading, with shares printed at $197.776 versus the prior regular-session close of $226, a -12.49% move. The most likely catalyst is the softer fiscal 2027 outlook tied to suspended ventilator sales after an FDA Class 1 recall, plus cost pressure from electronic components and freight. Because this is an extended-hours move, regular-session trading will confirm whether the repricing holds.
Key Takeaways
RMD printed at $197.776 after hours, down 12.49% from the $226 regular-session close.
The main pressure point is the soft FY27 outlook, linked to suspended ventilator sales after an FDA Class 1 recall.
ResMed still posted Q4 EPS of $2.95 versus a $2.90 estimate and FY26 revenue of about $5.65bn.
Investors should separate near-term guidance risk from the company’s strong sleep-health franchise and eight-quarter EPS beat streak.
What Is Behind ResMed Inc. (RMD) Falling After Hours
The clearest explanation comes from ResMed’s fiscal Q4 and fiscal 2026 results, reported Aug. 6. The company delivered a solid quarter, but its fiscal 2027 outlook was softer than investors expected. News coverage tied that outlook to suspended ventilator sales following an FDA Class 1 recall, macro uncertainty, and inflation affecting electronic components and freight.
That combination changes the short-term earnings picture. Ventilator sales represent only part of ResMed’s business, yet a sales pause removes revenue from the forecast while higher component and freight costs pressure margins. In plain English, the company can report strong historical results and still face a weaker earnings path ahead.
The timing also fits a post-earnings repricing rather than a fresh Aug. 12 headline. Robert W. Baird cut its RMD price target to $213 from $217 on Aug. 7, while KeyBanc lowered its target to $255 from $260 on the same date. Those cuts followed the earnings report and reinforced concerns about FY27 visibility.
The broader news tone does not point to a collapse in sentiment. RMD’s seven-day sentiment score was 0.9944, its 30-day score was 0.9851, and the trend was stable. That contrast matters. The after-hours selloff reflects hard concerns about forward guidance more than a broad news-sentiment breakdown.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
How ResMed’s Q4 Earnings and FY26 Financials Frame the Selloff
ResMed’s latest numbers do not describe a business in immediate retreat. Fiscal Q4 revenue reached about $1.46bn, while fiscal 2026 revenue totaled about $5.65bn, up 10% year over year. Q4 EPS came in at $2.95, above the $2.90 estimate, for a 1.7% surprise.
The earnings record is also constructive. ResMed beat EPS estimates in each of the last eight reported quarters. In fiscal Q3 2026, revenue grew 11%, non-GAAP gross margin expanded by 290 basis points, and EPS increased 21%. Therefore, the current issue is not a recent pattern of earnings misses. It is the market’s concern that the next phase of growth will be less smooth.
The valuation gives that concern weight. Market data lists RMD EPS at $10.66 and a P/E ratio of 21.09, with a market capitalization of $32.78B. The company also pays a 1.09% dividend yield, raised its quarterly dividend by 10% to $0.66, and completed a $1.4B share buyback program. Those figures support the case for financial strength, but they do not erase the effect of weaker FY27 visibility.
Why ResMed’s Sleep-Health Competitive Position Still Matters
ResMed remains a focused health technology company serving sleep apnea, respiratory care, and connected home-based treatment. Its products include CPAP, APAP, and bilevel devices, masks, accessories, cloud-connected tools, and digital health software. The company operates in more than 140 countries.
That model combines equipment sales with recurring demand for masks and accessories. It also gives ResMed a large connected-device base that supports patient monitoring and home-care workflows. ResMed identifies Philips BV and Fisher & Paykel Healthcare as primary competitors, while its brand, customer service, and product portfolio support a market-leading position.
The MatrixCare divestiture adds another strategic layer. On July 7, ResMed agreed to sell the business to Frazier Healthcare Partners. MatrixCare represented about $220M of revenue and $55M of non-GAAP operating profit based on preliminary FY2026 results. ResMed said the transaction would sharpen its focus on sleep, breathing health, and connected home care. That focus can improve the business mix, although the ventilator issue currently dominates the stock narrative.
For existing holders, the practical issue is position size. The Q4 EPS beat and eight-quarter beat streak argue against treating RMD as a broken company. However, suspended ventilator sales and higher input costs justify a more cautious view of near-term earnings.
For potential buyers, the after-hours print is not a complete investment signal. A disciplined approach avoids making a full allocation from one extended-hours quote and gives greater weight to regular-session price action, trading volume, and the market’s response to the FY27 outlook. The $180.27 52-week low is a prior price reference, not proof of a valuation floor.
Analyst sentiment has already cooled. RMD carries a consensus Hold rating, with 14 Buy ratings, 16 Holds, and five Sells. The consensus price target is $239.67, while the target range runs from $213 to $300. Those figures show that analysts still see upside from the after-hours price, but the wide range also signals disagreement over the impact of the recall and FY27 cost pressures.
ResMed’s after-hours decline is best understood as a forward-outlook shock, not a Q4 earnings failure. The core franchise continues to post growth, strong EPS execution, and shareholder returns, but the recall-linked ventilator pause has made the FY27 path less dependable. Regular-session trading will show whether investors view the drop as an overreaction or a fresh reset in RMD’s valuation.
RMD is down because investors are reacting to a softer fiscal 2027 outlook tied to suspended ventilator sales after an FDA Class 1 recall. Higher electronic component and freight costs are also weighing on margin expectations.
+Should I buy RMD stock now?
The stock may appeal to long-term investors, but the current drop reflects real guidance risk, so a full buy right away is not the most disciplined move. It is better to wait for regular-session confirmation and clearer visibility on FY27.
+Did ResMed miss earnings?
No. ResMed beat Q4 EPS estimates and posted solid full-year revenue growth, so the selloff is not being driven by an earnings miss. The market is focused on weaker forward guidance instead.
+Is the after-hours drop in RMD a buying opportunity?
It could be for investors who believe the recall-related headwind is temporary and that ResMed's core sleep-health business remains strong. Still, the move is based on extended-hours trading, so investors should wait for the regular session to judge whether the decline holds.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on RMD?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
